Please find enclosed disclosure received under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
SANOFI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sanofi India has received a final income tax assessment order from the Income Tax Department's Assessment Unit for FY 2022-23 (AY 2023-24). The order determines a tax liability of about INR 12.37 crore (including interest), arising from adjustments on transfer pricing issues and disallowance of payments made to healthcare professionals. The company received the order on 27th March 2026 and has stated it will file an appeal before higher tax authorities. The financial impact is being contested and is not yet final.
The INR 12.37 crore demand is not material relative to Sanofi India's overall size, but the company's plan to appeal means the actual cash outflow is uncertain. Short-term impact on the stock is expected to be limited.